Correlation between serum advanced glycation end-products and their receptor-mediated oxidative stress and perinatal outcomes in gestational diabetes mellitus

Figure 1 Flow diagram of the patient selection. GDM: Gestational diabetes mellitus; DM: Diabetes mellitus; BMI: Body mass index; AGE: Advanced glycation end-product; sRAGE: Soluble advanced glycation end-product receptor; RAGE: Advanced glycation end-product receptor.

Figure 2 Receptors for soluble advanced glycation end-product protein expression in placental tissues of pregnant women in the two groups. GDM: Gestational diabetes mellitus; sRAGE: Soluble advanced glycation end-product receptor; ^aP < 0.001.

Figure 3 Correlation of serum indicators in pregnant women in the gestational diabetes mellitus group. A: Correlation between serum advanced glycation end-products (AGEs) and soluble AGE receptor levels at 24-28 weeks of gestation and before delivery; B: Correlation between serum AGEs and superoxide dismutase levels at 24-28 weeks of gestation and before delivery; C: Correlation between serum AGEs and malondialdehyde levels at 24-28 weeks of gestation and before delivery. sRAGE: Soluble advanced glycation end-product receptor; SOD: Superoxide dismutase; MDA: Malondialdehyde; AGEs: Advanced glycation end-products.